Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Rhegmatogenous Retinal Detachment Clear all
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil Ophthalmic
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced May 22, 2026, 12:49 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Retinal Detachment With Multiple Breaks, Unspecified Eye, Proliferative Vitreoretinopathy
Interventions
Intravitreal aflibercept injection, Sham control
Drug · Other
Lead sponsor
M. Ali Khan, MD
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced May 22, 2026, 12:49 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment
Interventions
Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin, Prednisolone 1%, Atropine 1%
Procedure · Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced May 22, 2026, 12:49 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Retinal Detachment
Interventions
denufosol tetrasodium (INS37217) Intravitreal Injection
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
33
States / cities
Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced May 22, 2026, 12:49 AM EDT
Withdrawn Not applicable Interventional
View directory record Official record
Conditions
Epiretinal Membrane, Macular Hole, Visually Significant Vitreous Floater, Vitreomacular Traction, Vitreous Hemorrhage, Proliferative Diabetic Retinopathy, Rhegmatogenous Retinal Detachment, Retained Lens Material in the Posterior Segment
Interventions
UNITY Vitreoretinal Cataract System (VCS), CONSTELLATION Vision System, Vitreoretinal ophthalmic surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Scottsdale, Arizona • Laguna Hills, California • West Des Moines, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced May 22, 2026, 12:49 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Rhegmatogenous Macula-off Retinal Detachment
Interventions
400 ug Brimonidine Implant, 200 ug Brimonidine Implant, Sham (no implant)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Abilene, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced May 22, 2026, 12:49 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Retinal Detachment, Full Thickness Macular Hole, Epiretinal Membrane
Interventions
Pars plana vitrectomy, External drainage
Procedure
Lead sponsor
Allen C. Ho, MD
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced May 22, 2026, 12:49 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Retinal Detachment
Interventions
Retinal Detachment repair
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2016 · Synced May 22, 2026, 12:49 AM EDT
Terminated Early Phase 1 Interventional
View directory record Official record
Conditions
Retinal Detachment, Rhegmatogenous Retinal Detachment
Interventions
Lamivudine 300 MG, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced May 22, 2026, 12:49 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Vitreoretinopathy, Coats' Disease, Exudative Retinopathy, Lattice Degeneration, Retinal Hole, Sickler's Syndrome, Retinal Detachment Rhegmatogenous, Retinal Detachment Exudative, Retinal Detachment Traction
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Pred Forte
Drug
Lead sponsor
Lejla Vajzovic, MD, FASRS
Other
Eligibility
3 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced May 22, 2026, 12:49 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Retina; Detachment, Rhegmatogenous
Interventions
Retina re-attachment repair using C3F8 gas tamponade
Device
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Prairie Village, Kansas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 12:49 AM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
Methotrexate
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced May 22, 2026, 12:49 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment
Interventions
Methotrexate Injection, Methotrexate Infusion, Sham Injection
Drug
Lead sponsor
Cincinnati Eye Institute, Southwest Ohio
Other
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced May 22, 2026, 12:49 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced May 22, 2026, 12:49 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment - Macula Off
Interventions
ONL1204 Ophthalmic Solution, Sham treatment
Drug
Lead sponsor
ONL Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced May 22, 2026, 12:49 AM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Traction Retinal Detachments, Rhegmatogenous Retinal Detachments, Dislocated Intraocular Lens
Interventions
Intraocular assistance
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced May 22, 2026, 12:49 AM EDT